23 Participants Needed

Mirdametinib + BGB-3245 for Advanced Cancer

Recruiting at 13 trial locations
SC
Overseen BySpringWorks Clinical
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: SpringWorks Therapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate targeted therapy, or for which there is no treatment available, or prior standard of care therapy was not tolerated.

Are You a Good Fit for This Trial?

Adults with advanced solid tumors that haven't improved with at least one prior treatment, or when no other treatments are available. Participants must be over 18, have a performance status of ≤2 (which means they can do some light activity), and have specific genetic changes in their tumor related to the MAPK pathway. They should not have had recent cancer therapy or surgery, and cannot join if they have certain medical conditions like severe heart disease or uncontrolled infections.

Inclusion Criteria

Measurable disease per RECIST 1.1
Able to provide informed consent
My organs are functioning well and I haven't had a transfusion in the last 14 days.
See 5 more

Exclusion Criteria

I have a parathyroid disorder or had cancer-related high calcium levels.
I cannot swallow pills.
I haven't had cancer treatment in the last 2 weeks or 5 half-lives.
See 12 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive escalating doses of mirdametinib and BGB-3245 to determine the maximum tolerated dose

Up to 18 months

Dose Expansion

Participants receive the recommended phase 2 dose of mirdametinib and BGB-3245 to evaluate efficacy and safety

Up to 24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 36 months

What Are the Treatments Tested in This Trial?

Interventions

  • BGB-3245
  • Mirdametinib
Trial Overview The trial is testing a combination of two drugs: Mirdametinib and BGB-3245. It's an early-phase study where doses are increased gradually to find safe levels before expanding to more patients. The goal is to see how well these drugs work together against different types of solid tumors with mutations affecting cell growth pathways.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: Phase 2 Dose Expansion CExperimental Treatment2 Interventions
Group II: Phase 2 Dose Expansion BExperimental Treatment2 Interventions
Group III: Phase 2 Dose Expansion AExperimental Treatment2 Interventions
Group IV: Phase 1 Dose Escalation Cohorts Ranging in DoseExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

SpringWorks Therapeutics, Inc.

Lead Sponsor

Trials
14
Recruited
900+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security